Literature DB >> 32585186

Children with COVID-19 at a specialist centre: initial experience and outcome.

Richard W Issitt1, John Booth2, William A Bryant2, Anastasia Spiridou2, Andrew M Taylor3, Pascale du Pré2, Pad Ramnarayan2, John Hartley2, Maria Cortina-Borja4, Karyn Moshal2, Helen Dunn2, Harry Hemingway5, Neil J Sebire2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32585186      PMCID: PMC7308787          DOI: 10.1016/S2352-4642(20)30204-2

Source DB:  PubMed          Journal:  Lancet Child Adolesc Health        ISSN: 2352-4642


× No keyword cloud information.
The 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, characterised by potentially severe respiratory and gastrointestinal symptoms, in humans. As of late May, 2020, there were around 5 million confirmed cases of COVID-19 and more than 300 000 associated deaths globally. COVID-19 can affect children, but it appears to be associated with fewer symptoms and less severe disease compared with adults, with correspondingly lower case-fatality rates. In the UK, Public Health England has outlined a shielding strategy designed to protect those extremely vulnerable to SARS-CoV-2 infection,3, 4 such as individuals who are immunocompromised. We examined a cohort of paediatric patients, presenting to Great Ormond Street Hospital, London, UK (a specialist children's hospital), with suspected COVID-19 to document their clinical characteristics and outcomes with regard to the presence of underlying medical conditions associated with vulnerability. We retrospectively used routinely collected deidentified hospital data within a secure digital research environment (REC approval 17/LO/0008) from children presenting to Great Ormond Street Hospital, with suspected COVID-19 between March 1 and May 15, 2020. COVID-19 positive cases were those with clinical features of COVID-19 and a positive PCR-test for SARS-CoV-2 (either directly or positive familial SARS-CoV-2 testing). Patients were classified regarding vulnerability group using NHS Digital methodology. There were 65 COVID-19 postive cases (median age 9 years [IQR 0·9–14]) during the study (appendix), of whom 31 (48%) were classed as vulnerable. The most common provisional diagnosis codes for the group were sepsis, fever, and pneumonia. Only one patient who tested positive for SARS-CoV-2 died because of an underlying medical condition and another infection not thought to be related to SARS-CoV-2. 29 (45%) patients required admission to the intensive care unit. Of whom, 14 (48%) were classed as vulnerable. The length of stay in the intensive care unit for all patients was 4 days (2·4–10·6). Compared with patients classed as non-vulnerable, those classed as vulnerable had a significantly longer stay of 11 days (3·7–15·1; Mann-Whitney U test p<0·001). Of the 29 patients admitted to the intensive care unit, 18 (62%) required mechanical ventilation, of whom ten (56%) were classed as vulnerable (p=0·53). Overall hospital stay was also significantly shorter in the non-vulnerable group (3·9 days [2·5–15·7]) than in the vulnerable group (16·2 days [3·8–20·8]; p<0·001). As of May 15, 2020, nine patients (14%) remained in hospital, three of whom (33%) were classed as vulnerable (p=0·35). During the study, with a daily average of 326 inpatients, on average ten were positive for SARS-CoV-2 at any time, representing around 3% of the hospital inpatient population, much lower than the estimated 25% COVID-19-positive population reported across adult London trusts. These data show the characteristics and outcomes of children presenting to a specialist children's hospital with clinical features of COVID-19 disease and positive testing, and confirm that some children with SARS-CoV-2 might have severe disease with requirement for intensive care admission. Of note, the reported cohort of patients are highly preselected, both for children with severe disease and for those with underlying medical conditions, and therefore the findings are not applicable to the general paediatric population. Stewart and colleagues recently reported specific renal features in a case series of 52 children with COVID-19 referred to our centre, 35 of whom are also included in the present overall cohort. Previous data from general centres suggest that less than 1% of COVID-19 admissions are children younger than 18 years and data from multiple North American hospitals reported few paediatric patients with COVID-19 per intensive care unit.7, 8 As such, the present cohort disproportionately represents those with complex underlying medical conditions, consistent with the fact that around three quarters of inpatients registered with the hospital in 2019 would be considered as vulnerable according to COVID-19 guidance. This is not unexpected because the hospital represents a centre for paediatric transplantation, genetic diseases (such as congenital immunodeficiency), and paediatric malignancy. Furthermore, in children with confirmed COVID-19, the proportion of patients with underlying vulnerable conditions requiring admission to an intensive care unit for mechanical ventilation were not significantly different to those classed as non-vulnerable. Although the possible effects of lockdown and shielding remain undetermined, given that this series includes cases from before and during lockdown (since March 23, 2020), these data raise the possibility that underlying medical conditions that place children at increased risk of COVID-19 disease or complications might differ from adults. This is consistent with a study reporting no mortality in a multicentre cohort of patients with cystic fibrosis affected by COVID-19, and another using a renal registry, suggesting that children receiving immunosuppressive treatment appear to have a mild COVID-19 clinical course. Susceptibility for COVID-19 in vulnerable groups might therefore be both disease-specific and related to patient age. In addition to the typical features of COVID-19 disease described in adults, although most children who are infected appear to have mild disease, some might have an unusual associated systemic inflammatory condition: paediatric inflammatory multisystem syndrome temporally related to SARS-CoV-2 infection (PIMS-TS). The criteria for the definitive diagnosis of PIMS-TS are evolving, and it remains uncertain whether any of the current patients with COVID could represent such cases, and studies are underway examining the PIMS-TS phenomenon. Limitations of these data include the retrospective nature of using routine data, absence of a matched control group, and the highly preselected population from a specialist children's hospital, which is not representative of the paediatric population as a whole, although these data do provide information regarding this potentially high-risk group. It should also be noted that since vulnerable children might be shielded, the pattern of presentation reported might not be representative of a non-shielded situation, and additional epidemiological studies are required.
  7 in total

1.  Impact of Coronavirus disease (COVID-19) pandemic on health professionals.

Authors:  Bilal Ahmed Sethi; Ahsan Sethi; Sadaf Ali; Hira Shireen Aamir
Journal:  Pak J Med Sci       Date:  2020-05       Impact factor: 1.088

2.  Children with Covid-19 in Pediatric Emergency Departments in Italy.

Authors:  Niccolò Parri; Matteo Lenge; Danilo Buonsenso
Journal:  N Engl J Med       Date:  2020-05-01       Impact factor: 91.245

3.  Renal dysfunction in hospitalised children with COVID-19.

Authors:  Douglas J Stewart; John C Hartley; Mae Johnson; Stephen D Marks; Pascale du Pré; Jelena Stojanovic
Journal:  Lancet Child Adolesc Health       Date:  2020-06-15

4.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

5.  Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units.

Authors:  Lara S Shekerdemian; Nabihah R Mahmood; Katie K Wolfe; Becky J Riggs; Catherine E Ross; Christine A McKiernan; Sabrina M Heidemann; Lawrence C Kleinman; Anita I Sen; Mark W Hall; Margaret A Priestley; John K McGuire; Konstantinos Boukas; Matthew P Sharron; Jeffrey P Burns
Journal:  JAMA Pediatr       Date:  2020-09-01       Impact factor: 16.193

6.  The severity of COVID-19 in children on immunosuppressive medication.

Authors:  Matko Marlais; Tanja Wlodkowski; Marina Vivarelli; Lars Pape; Burkhard Tönshoff; Franz Schaefer; Kjell Tullus
Journal:  Lancet Child Adolesc Health       Date:  2020-05-13

7.  A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis.

Authors:  Rebecca Cosgriff; Susannah Ahern; Scott C Bell; Keith Brownlee; Pierre-Régis Burgel; Cass Byrnes; Harriet Corvol; Stephanie Y Cheng; Alexander Elbert; Albert Faro; Christopher H Goss; Vincent Gulmans; Bruce C Marshall; Edward McKone; Peter G Middleton; Rasa Ruseckaite; Anne L Stephenson; Siobhán B Carr
Journal:  J Cyst Fibros       Date:  2020-04-25       Impact factor: 5.482

  7 in total
  5 in total

1.  Impact of the COVID-19 pandemic on radiology appointments in a tertiary children's hospital: a retrospective study.

Authors:  Dean Langan; Susan Shelmerdine; Andrew Taylor; William A Bryant; John Booth; Neil J Sebire; Owen Arthurs; Mario Cortina-Borja
Journal:  BMJ Paediatr Open       Date:  2021-08-11

2.  Evolution of viral variants in remdesivir-treated and untreated SARS-CoV-2-infected pediatrics patients.

Authors:  Florencia A T Boshier; Juanita Pang; Justin Penner; Matthew Parker; Nele Alders; Alasdair Bamford; Louis Grandjean; Stephanie Grunewald; James Hatcher; Timothy Best; Caroline Dalton; Patricia Dyal Bynoe; Claire Frauenfelder; Jutta Köeglmeier; Phoebe Myerson; Sunando Roy; Rachel Williams; Thushan I de Silva; Richard A Goldstein; Judith Breuer
Journal:  J Med Virol       Date:  2021-09-04       Impact factor: 20.693

3.  Survival and Complications in Pediatric Patients With Cancer and COVID-19: A Meta-Analysis.

Authors:  Elisa Dorantes-Acosta; Diana Ávila-Montiel; Miguel Klünder-Klünder; Luis Juárez-Villegas; Horacio Márquez-González
Journal:  Front Oncol       Date:  2021-01-21       Impact factor: 6.244

4.  Acute symptoms in SARS-CoV-2 positive adolescents aged 15-18 years - Results from a Danish national cross-sectional survey study.

Authors:  Selina Kikkenborg Berg; Pernille Palm; Susanne Dam Nielsen; Ulrikka Nygaard; Henning Bundgaard; Camilla Rotvig; Anne Vinggaard Christensen
Journal:  Lancet Reg Health Eur       Date:  2022-03-24

5.  Coronavirus disease-19 deaths among children and adolescents in an area of Northeast, Brazil: why so many?

Authors:  Aline de Siqueira Alves Lopes; Sarah Cristina Fontes Vieira; Roseane Lima Santos Porto; Victor Santana Santos; Debora Cristina Fontes Leite; Luis Eduardo Cuevas; Ricardo Queiroz Gurgel
Journal:  Trop Med Int Health       Date:  2020-12-06       Impact factor: 3.918

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.